A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT02031458. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Multicenter, Single-Arm Study OF Atezolizumab In Patients With PD-L1-Positive Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This multicenter, single-arm study will evaluate the efficacy and safety of Atezolizumab in participants with PD-L1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). Participants will receive Atezolizumab 1200 milligrams (mg) intravenously every 3 weeks as long as participants are experiencing clinical benefit as assessed by the investigator, that is , in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression.
Study identification
- NCT ID
- NCT02031458
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 667 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 21, 2014
- Primary completion
- May 27, 2015
- Completion
- Jan 10, 2019
- Last update posted
- Jan 5, 2020
2014 – 2019
United States locations
- U.S. sites
- 37
- U.S. states
- 22
- U.S. cities
- 34
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner MD Anderson Cancer Center | Gilbert | Arizona | 85234 | — |
| HonorHealth Research Institute - Bisgrove | Scottsdale | Arizona | 85258 | — |
| City of Hope Comprehensive Cancer Center | Duarte | California | 91010 | — |
| Angeles Clinic & Rsch Inst | Los Angeles | California | 90025 | — |
| City of Hope National Medical Group | South Pasadena | California | 91030 | — |
| Stanford Cancer Center | Stanford | California | 94305-5820 | — |
| University of Colorado Health Science Center; Biomedical Research Bldg. Room 511 | Aurora | Colorado | 80045 | — |
| Yale Cancer Center; Medical Oncology | New Haven | Connecticut | 06520 | — |
| Georgetown University Medical Center Lombardi Cancer Center | Washington D.C. | District of Columbia | 20007 | — |
| Florida Cancer Specialists; SCRI | Fort Myers | Florida | 33901 | — |
| Florida Hospital Cancer Inst | Orlando | Florida | 32804 | — |
| Hematology Oncology Associates of the Treasure Coast | Port Saint Lucie | Florida | 34952 | — |
| Florida Cancer Specialists. | St. Petersburg | Florida | 33705 | — |
| Emory Uni - Winship Cancer Center; Hematology/Oncology | Atlanta | Georgia | 30322 | — |
| Northwest Georgia Oncology Centers PC - Marietta | Marietta | Georgia | 30060 | — |
| Northwestern University; Robert H. Lurie Comp Can Ctr | Chicago | Illinois | 60611 | — |
| University Of Chicago Medical Center; Section Of Hematology/Oncology | Chicago | Illinois | 60637 | — |
| Uni of Maryland; Greenebaum Cancer Center | Baltimore | Maryland | 21201 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Beth Israel Deaconess Med Ctr; Hem/Onc | Boston | Massachusetts | 02215 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Dartmouth Hitchcock Medical Center | Lebanon | New Hampshire | 03756 | — |
| Monter Cancer Center | Lake Success | New York | 11042 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Carolina BioOncology Institute, PLCC | Huntersville | North Carolina | 28078 | — |
| Oncology Hematology Care Inc | Cincinnati | Ohio | 45242 | — |
| The Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | — |
| Ohio State University; B406 Starling-Loving Hall | Columbus | Ohio | 43210 | — |
| Penn State Milton S. Hershey Medical Center | Hershey | Pennsylvania | 17033 | — |
| Fox Chase Cancer Center; Hematology/Oncology | Philadelphia | Pennsylvania | 19111 | — |
| Tennessee Oncology PLLC - Nashville (20th Ave) | Nashville | Tennessee | 37203 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Huntsman Cancer Institute; University of Utah | Salt Lake City | Utah | 84112 | — |
| University of Virginia; Office of Sponsored Programs | Charlottesville | Virginia | 22902 | — |
| University of Washington Seattle Cancer Care Alliance | Seattle | Washington | 98195 | — |
| University of Wisconsin | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 73 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02031458, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 5, 2020 · Synced Sep 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02031458 live on ClinicalTrials.gov.